Mirum Pharmaceuticals (NASDAQ:MIRM) PT Raised to $66.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price raised by analysts at HC Wainwright from $58.00 to $66.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 125.64% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, May 9th. Citigroup boosted their price target on shares of Mirum Pharmaceuticals from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday. JMP Securities reduced their price objective on shares of Mirum Pharmaceuticals from $72.00 to $66.00 and set a “market outperform” rating for the company in a report on Thursday, May 9th. Finally, Morgan Stanley cut their target price on Mirum Pharmaceuticals from $57.00 to $53.00 and set an “overweight” rating on the stock in a research report on Friday, May 10th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $53.64.

Mirum Pharmaceuticals Stock Down 11.4 %

Mirum Pharmaceuticals stock opened at $29.25 on Monday. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $1.38 billion, a PE ratio of -7.88 and a beta of 1.10. The firm’s fifty day moving average is $25.32 and its 200 day moving average is $27.23. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The company had revenue of $69.22 million for the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. As a group, sell-side analysts predict that Mirum Pharmaceuticals will post -1.39 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were purchased at an average price of $24.80 per share, with a total value of $49,600.00. Following the transaction, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at $347,200. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at approximately $748,535.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Eric Bjerkholt acquired 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The stock was acquired at an average price of $24.80 per share, with a total value of $49,600.00. Following the completion of the purchase, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The disclosure for this purchase can be found here. 22.87% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Avidity Partners Management LP bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at $36,114,000. First Turn Management LLC bought a new position in Mirum Pharmaceuticals in the 4th quarter worth about $24,688,000. Janus Henderson Group PLC grew its holdings in Mirum Pharmaceuticals by 34.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after buying an additional 704,659 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at about $21,014,000. Finally, Cadian Capital Management LP lifted its holdings in shares of Mirum Pharmaceuticals by 34.8% in the fourth quarter. Cadian Capital Management LP now owns 1,934,922 shares of the company’s stock worth $57,119,000 after buying an additional 500,000 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.